GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » EV-to-EBIT

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) EV-to-EBIT : -2.76 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Spectrum Pharmaceuticals's Enterprise Value is $184.88 Mil. Spectrum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-67.06 Mil. Therefore, Spectrum Pharmaceuticals's EV-to-EBIT for today is -2.76.

The historical rank and industry rank for Spectrum Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

SPPI' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.56   Med: -6.32   Max: 30.36
Current: -2.76

During the past 13 years, the highest EV-to-EBIT of Spectrum Pharmaceuticals was 30.36. The lowest was -31.56. And the median was -6.32.

SPPI's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.41 vs SPPI: -2.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Spectrum Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $127.45 Mil. Spectrum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-67.06 Mil. Spectrum Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -52.62%.


Spectrum Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Spectrum Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals EV-to-EBIT Chart

Spectrum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.95 -1.35 -1.88 -0.69 -0.38

Spectrum Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 -0.63 -0.15 -0.38 -1.90

Competitive Comparison of Spectrum Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Spectrum Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectrum Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's EV-to-EBIT falls into.



Spectrum Pharmaceuticals EV-to-EBIT Calculation

Spectrum Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=184.878/-67.06
=-2.76

Spectrum Pharmaceuticals's current Enterprise Value is $184.88 Mil.
Spectrum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spectrum Pharmaceuticals  (NAS:SPPI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Spectrum Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 ) =EBIT / Enterprise Value (Q: Mar. 2023 )
=-67.06/127.45075
=-52.62 %

Spectrum Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $127.45 Mil.
Spectrum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spectrum Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Executives
Juhyun Lim director 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan officer: See Remarks C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan officer: Chief Legal Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga director, officer: CEO & President 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel officer: Chief Medical Officer 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas director 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson officer: EVP & Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon officer: Chief Commercial Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner director 157 TEHCNOLOGY DRIVE, IRVINE CA 92618

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Headlines

From GuruFocus